» Articles » PMID: 38470112

Two-way Pharmacodynamic Modeling of Drug Combinations and Its Application to Pairs of Repurposed Ebola and SARS-CoV-2 Agents

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Existing pharmacodynamic (PD) mathematical models for drug combinations discriminate antagonistic, additive, multiplicative, and synergistic effects, but fail to consider how concentration-dependent drug interaction effects may vary across an entire dose-response matrix. We developed a two-way pharmacodynamic (TWPD) model to capture the PD of two-drug combinations. TWPD captures interactions between upstream and downstream drugs that act on different stages of viral replication, by quantifying upstream drug efficacy and concentration-dependent effects on downstream drug pharmacodynamic parameters. We applied TWPD to previously published drug matrixes for repurposed potential anti-Ebola and anti-SARS-CoV-2 drug pairs. Depending on the drug pairing, the model recapitulated combined efficacies as or more accurately than existing models and can be used to infer efficacy at untested drug concentrations. TWPD fits the data slightly better in one direction for all drug pairs, meaning that we can tentatively infer the upstream drug. Based on its high accuracy, TWPD could be used in concert with PK models to estimate the therapeutic effects of drug pairs .

Citing Articles

Efficient assay for evaluating drug efficacy and synergy against emerging SARS-CoV-2 strains.

Woodall M, Ellis S, Zhang S, Kembou-Ringert J, Kite K, Buggiotti L Antimicrob Agents Chemother. 2024; 69(2):e0123324.

PMID: 39688407 PMC: 11823597. DOI: 10.1128/aac.01233-24.


A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy.

Esmaeili S, Owens K, Wagoner J, Polyak S, White J, Schiffer J Nat Commun. 2024; 15(1):5478.

PMID: 38942778 PMC: 11213957. DOI: 10.1038/s41467-024-49458-9.


A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral rebound.

Esmaeili S, Owens K, Wagoner J, Polyak S, White J, Schiffer J medRxiv. 2024; .

PMID: 38352583 PMC: 10862980. DOI: 10.1101/2023.08.23.23294505.

References
1.
Hulseberg C, Feneant L, Szymanska-de Wijs K, Kessler N, Nelson E, Shoemaker C . Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses. J Virol. 2019; 93(8). PMC: 6450122. DOI: 10.1128/JVI.02185-18. View

2.
Cheng Y, Williamson P, Zheng W . Improving therapy of severe infections through drug repurposing of synergistic combinations. Curr Opin Pharmacol. 2019; 48:92-98. PMC: 6858965. DOI: 10.1016/j.coph.2019.07.006. View

3.
Warren T, Jordan R, Lo M, Ray A, Mackman R, Soloveva V . Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016; 531(7594):381-5. PMC: 5551389. DOI: 10.1038/nature17180. View

4.
Johansen L, Brannan J, Delos S, Shoemaker C, Stossel A, Lear C . FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med. 2013; 5(190):190ra79. PMC: 3955358. DOI: 10.1126/scitranslmed.3005471. View

5.
Pecheur E, Borisevich V, Halfmann P, Morrey J, Smee D, Prichard M . The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses. J Virol. 2016; 90(6):3086-92. PMC: 4810626. DOI: 10.1128/JVI.02077-15. View